Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 that develops targeted treatments for hypertension and related cardio-renal-metabolic diseases. Its lead candidate, lorundrostat (MLS-101), is a highly selective aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharmaceutical Company in 2020. The drug targets dysregulated aldosterone, an underlying cause of hypertension which, by the company's figures, affects approximately 30% of people managing the condition.

Lorundrostat's phase 2 proof-of-concept study was published in JAMA, and the compound has since been advanced through the Launch-HTN and Advance-HTN clinical trials. The work sits at the intersection of clinical-stage drug development, aldosterone synthase inhibition and cardio-renal-metabolic therapeutics.

The company operates as a fully remote team and is a Great Place to Work-certified employer. Its stated working culture places collaboration at the core of the work ethic, with an emphasis on leveraging colleagues' strengths and maintaining a supportive environment where every voice is heard.